Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
UroGen Pharma Ltd. URGN
$12.14
-$0.27 (-2.25%)
На 18:01, 12 мая 2023
+89.46%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
280448844.00000000
-
week52high
16.11
-
week52low
4.85
-
Revenue
64357000
-
P/E TTM
-3
-
Beta
0.74671200
-
EPS
-5.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Berenberg | Buy | 27 апр 2022 г. | |
| Goldman Sachs | Neutral | Neutral | 22 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 янв 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 27 апр 2021 г. |
| Oppenheimer | Outperform | Outperform | 17 апр 2020 г. |
| Goldman Sachs | Neutral | Neutral | 06 сент 2022 г. |
| Berenberg | Buy | 06 сент 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Barrett Elizabeth A. | A | 100000 | 100000 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 125000 | 125000 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 75000 | 75000 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 13334 | 13333 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 0 | 5000 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 326691 | 13333 | 31 янв 2023 г. |
| Barrett Elizabeth A. | A | 313358 | 5000 | 31 янв 2023 г. |
| Kim Dong | A | 38000 | 38000 | 31 янв 2023 г. |
| Kim Dong | A | 10000 | 10000 | 31 янв 2023 г. |
| Schoenberg Mark | A | 30000 | 30000 | 31 янв 2023 г. |
Новостная лента
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
16 мар 2023 г. в 10:42
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma to Present at Upcoming Investor Conferences
Business Wire
01 мар 2023 г. в 16:00
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March: Cowen 43rd Annual Health Care Conference — March 7-9, 2023 Panel Presentation Date: Tuesday, March 7th from 12:50-1:50pm ET Webcast Link: https://wsw.
UroGen: Struggling With Revenue And With Cash Runway
Seeking Alpha
08 февр 2023 г. в 04:04
UroGen has an approved drug and a platform. However, there's not much growth in revenue.
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
Seeking Alpha
21 ноя 2022 г. в 13:30
Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bladder cancers due to its ability to allow molecules to reside in the target space for an extended period of time.
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 12:05
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director-Investor Relations Liz Barrett - President & Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Don Kim - Chief Financial Officer Conference Call Participants Dipesh Patel - H.C.